189 results about "Protein antigen" patented technology

The invention discloses a porcine epidemic diarrhea virus antigen fusion protein, a coding gene and a porcine epidemic diarrhea vaccine prepared from the porcine epidemic diarrhea virus antigen fusion protein. The method comprises the following steps: screening to obtain a homosensory sequence of the spike protein of the porcine epidemic diarrhea virus, and fusing the homosensory sequence with a monomeric porcine ferritin heavy chain subunit to obtain an antigen fusion protein; in order to improve the expression quantity or the titer of the antigen fusion protein, the obtained antigen fusion protein is subjected to sequence optimization and then subjected to single-site or multi-site mutation, and the expression quantity and the titer of the obtained mutant are remarkably improved. According to the invention, a recombinant protein is expressed by using a silkworm or AcMNPV-insect cell and other eukaryotic expression systems to obtain a self-assembled ferritin nanoparticle antigen for displaying an S protein antigen protein on the surface of a cage structure of porcine ferritin, and a vaccine prepared from the prepared nanoparticle antigen can induce a widely neutralized anti-porcine epidemic diarrhea virus antibody; the porcine epidemic diarrhea virus vaccine has the potential of becoming a universal porcine epidemic diarrhea virus vaccine with cross immune efficacy.

The invention discloses a self-replicating RNA (Ribonucleic Acid) molecule, a porcine rotavirus RNA vaccine and application thereof, and relates to the technical field of vaccines. According to the present invention, the coding sequence of the porcine rotavirus G9P23 type VP4 protein is optimized, such that the fact that the saRNA prepared by using the nucleotide sequence represented by the SEQ ID NO: 10 can secrete the high porcine rotavirus G9P23 type VP4 protein antigen after the cell transfection is found; after the optimized porcine rotavirus G9P23 type VP4 protein is used for immunizing experimental animals, the level of neutralizing antibodies generated by the animals can be improved, and the challenge protection effect is enhanced. Therefore, the nucleic acid molecule provided by the invention can be used for developing drugs and vaccines for causing protective immune response in experimental animal bodies. Compared with a traditional vaccine, the vaccine provided by the invention has good immunogenicity and safety, and has a good application prospect.

The invention relates to the technical field of HPV therapeutic vaccines, in particular to an MATV51 recombinant adenovirus vector, application, a preparation method and an HPV 16 / 18 / 52 therapeutic vaccine. The MATV51 recombinant adenovirus vector comprises nucleotide sequences used for coding E6 and E7 antigens of HPV16, HPV18 and HPV52, and further comprises a nucleotide sequence used for coding CD40L. A nucleotide sequence of the recombinant adenovirus vector is designed aiming at an HPV16 / 18 / 52E6-E7 protein antigen and contains a nucleotide sequence for coding CD40L, and the expressed fusion protein takes CD40L as an adjuvant; the HPV 16 / 18 / 52 therapeutic vaccine can cover genotypes of three HPV viruses at the same time, and has good immune effect and memory effect, so that the effect of the vaccine is effectively improved, and the application range is wide.

Disclosed herein are compositions comprising protein antigens and RNA encoding the same (e.g., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can result in an improved immune response as compared to current SARS-COV-2 vaccines.

The invention belongs to the field of biological detection, and particularly relates to a cardiac troponin I fragment, a product prepared from the cardiac troponin I fragment and application of the cardiac troponin I fragment. According to the specific technical scheme, the protein fragment comprises a cTnI (31-164) protein fragment, an HSP65 (187-375) protein fragment and a protein fragment combination. The invention provides a protein antigen or composition for detecting acute myocardial infarction, the detection specificity and sensitivity are ideal, and the protein antigen or composition can be further prepared into related reagents or kits according to needs.

The invention discloses a nano antibody targeting GPRC5D as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The nano antibody is generated by mixed immunization of a GPRC5D polypeptide antigen with a sequence shown as SEQ ID NO: 1 and a GPRC5D protein antigen with a sequence shown as SEQ ID NO: 2. The preparation method comprises the following steps: mixing the GPRC5D polypeptide antigen and the GPRC5D protein antigen to immunize alpaca, sampling blood, constructing an antibody library, screening a phage display antibody library, expressing protein, and selecting the nano antibody with the highest affinity. The invention further provides a radionuclide labeled molecular probe, the nano antibody is small in molecular weight and can recognize a large number of epitopes, and the molecular probe prepared from the nano antibody can obtain high-quality images, is used for preparing products for developing multiple myeloma or detecting GPRC5D expression level and has wide application prospects.

The invention provides a bovine akabane disease virus recombinant N protein antigen, a preparation method and an ELISA kit, relates to the field of biotechnology detection, and solves the problems that in the prior art, a competitive ELISA technical means is generally adopted in an ELISA detection method, the preparation cost is high, the price of a commercialized kit is high, and the detection cost is low. The development of beef cattle breeding enterprises in China is not facilitated. The amino acid sequence of the bovine akabane disease virus recombinant N protein antigen is as shown in SEQ ID No.2. The bovine akabane disease virus recombinant N protein antigen obtained in the invention can be specifically combined with an antibody of bovine akabane disease virus through verification, and can be used as a candidate antigen for bovine akabane disease virus detection; the ELISA detection kit developed by the invention can be used for detecting the bovine akabane disease virus antibody, and has the advantages of strong specificity, high sensitivity, good repeatability, low cost, large-scale detection and the like.

The invention discloses an ILTV gD protein antigen epitope expression cassette, a recombinant virus and application, and relates to the field of gene and protein engineering. The ILTV gD protein antigen epitope expression cassette provided by the invention comprises T and B cell epitopes of gD protein derived from an infectious laryngotracheitis virus WG strain. The recombinant virus rH120-gD-T / B is obtained by replacing a 5ab gene of an infectious bronchitis virus H120 strain with a gene for coding an ILTV gD protein antigen epitope expression cassette. The recombinant virus has good genetic stability, can be used for developing a safe and effective IB-ILT bivalent live vector vaccine, and solves the problem of poor stability of the current recombinant IBV.

A method for treatment or prophylaxis of a disease in a subject involving administering to the subject a vaccine composition including non-immunomodulating, engineered, plant-derived extracellular vesicles (EVs), is provided. The Evs are loaded with an exogenous nucleic acid molecule encoding a protein antigen. The disease is an infectious disease or cancer. A method for the preparation of the vaccine composition, which makes use of one or more polycationic substances and one or more sugar molecules is also provided.

The present invention relates to the field of biotechnology. Specifically, the present invention provides a monoclonal antibody, preparation method, and application of tyrosine iodinated EGFR protein. The present invention prepares tyrosine iodinated EGFR protein antigen peptides, immunizes mice to prepare monoclonal antibodies, and utilizes phage display technology to select and express relevant antibodies using expression vectors. ELISA screening and immunohistochemistry and cell fluorescence detection yield two highly sensitive and specific monoclonal antibodies, M018 and M025. The monoclonal antibodies obtained by screening can be used for the detection and monitoring of tyrosine iodinated modification at position 845 of the EGFR protein, providing support for tumor diagnosis and the development of anti-tumor drugs.

T cell responses are exquisitely antigen-specific and directed against peptide epitopes displayed by human leukocyte antigen (HLA) on the surface of presenting cells. In particular, class II HLA (HLA-II) is remarkably polymorphic, which allows for presentation of diverse peptide antigens to T cells, but also forms the basis for genetic associations with diverse immunopathologies across the spectrum of infectious disease and autoimmunity. Here, Applicants employ monoallelic immunopeptidomics to retrieve over 200,000 unique peptides presented by 41 HLA-II heterodimers covering major alleles across diverse ancestries. Applicants leveraged this expansive dataset to develop computational models that predict peptide antigens based on HLA-II binding properties and infer informative features of the protein antigens from which these peptides derive. Combining both peptide and (contextual) protein features, Applicants develop Context Aware Predictor of T cell Antigens (CAPTAn) to discover novel T cell epitopes from prokaryotes in the human microbiome and the viral pandemic pathogen SARS-COV-2.

The invention discloses an mRNA (messenger ribonucleic acid) vaccine for preventing and / or treating pseudorabies and application of the mRNA vaccine. Codon optimization is performed on a gene sequence of a pseudorabies virus gD protein antigen to obtain an optimized gene sequence of the pseudorabies virus gD protein antigen; the pseudorabies virus truncated gD protein antigen is obtained by optimizing the sequence of the pseudorabies virus gD protein antigen, the gene sequence of the truncated gD protein antigen is subjected to codon optimization, and experiments show that the optimized pseudorabies virus truncated gD protein antigen has higher expression quantity; the sequence-optimized pseudorabies virus truncated gD protein is further prepared into an mRNA vaccine, and after the mRNA vaccine is used for immunizing mice and piglets, it is found that the mRNA vaccine of the sgD protein can play an immune protection role on the mice and the piglets, and the mRNA vaccine is obviously superior to commercially available pseudorabies inactivated vaccines.

The invention discloses a vaccine composition and a preparation method thereof, the vaccine composition comprises a first component and a second component, the first component is a recombinant protein antigen, the second component is an oil-in-water composite adjuvant, and the oil-in-water composite adjuvant comprises a water phase, an oil phase, an emulsifier, a Toll-like receptor stimulant and / or an STING stimulant. The vaccine composition provided by the invention can stimulate a body to generate a high-level specific IgG antibody and a neutralizing antibody, and has a good cellular immune effect at the same time. The second component provided by the invention is simple in preparation process, low in cost, stable in dosage form, easy to store and good in immune effect, and has a wide application prospect in vaccine or drug development.

This invention relates to compositions (e.g. immunogenic compositions) which can be used to immunise against C. acnes. The compositions comprise C. acnes antigens and antigen combinations, used in the form of nucleic acids (e.g. mRNAs) encoding antigenic proteins or in the form of recombinant protein antigens.

The present invention relates to compositions (e.g., vaccine compositions) useful for immunizing against Chlamydia infection. These compositions comprise Chlamydia species antigens and antigen combinations that can be used to immunize against Chlamydia species, which antigens and antigen combinations are used in the form of nucleic acids (e.g., mRNA) encoding antigen proteins or in the form of recombinant protein antigens.

The application discloses a vaccine and a preparation method thereof, and the preparation method comprises the following steps: mixing an acidic protein antigen solution containing a phosphate buffer solution with an aluminum adjuvant to make the molar ratio of phosphorus and aluminum below 0.9, so as to obtain an acidic protein vaccine; or mixing the aluminum adjuvant with a solution containing phosphate ions to make the molar ratio of phosphorus and aluminum above 0.2, and then mixing the aluminum adjuvant with an alkaline protein antigen solution containing a phosphate buffer solution, so as to obtain an alkaline protein vaccine; wherein the acidic protein antigen is any kind of protein antigen with a net negative charge; and the alkaline protein antigen is any kind of protein antigen with a net positive charge. According to the preparation method, the molar ratio of phosphorus and aluminum is adjusted to a specific range according to the net charge of the protein antigen, so that the isoelectric point of the aluminum adjuvant can be effectively changed, the charge carried by the aluminum adjuvant is opposite to the charge carried by the protein antigen, and then the aluminum adjuvant and the protein antigen are attracted to each other through electrostatic interaction. The vaccine antigen prepared by the method has high antigen adsorption rate and good stability, the preparation method is simple, and the method is suitable for industrial application.

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.

The present invention discloses a recombinant porcine circovirus type 3 trimer protein, a preparation method and an application thereof. The present invention uses bioinformatics methods and resources to predict the B cell antigen epitopes and T cell antigen epitopes of the PCV3Cap protein. Taking into account the stability and immunogenicity of the antigen epitopes, a recombinant porcine circovirus type 3 trimer protein based on the PCV3Cap protein antigen epitope is designed, and its efficient soluble expression in Escherichia coli is achieved. The expressed recombinant porcine circovirus type 3 trimer protein can be mass-produced and purified by Ni-NTA affinity chromatography. The purified recombinant porcine circovirus type 3 trimer protein can assemble into a stable trimer structure. The subunit vaccine prepared using the recombinant porcine circovirus type 3 trimer protein can induce experimental pigs to produce a high level of antibodies and has a significant protective effect on the experimental pigs. The recombinant porcine circovirus type 3 trimer protein designed by the present invention provides a new idea for the development of PCV3 vaccine.

The invention provides a preparation method and application of a nitrogen-containing heterocyclic micromolecule modified polyethyleneimine polymer derivative. Compared with a polyethyleneimine polymer, the nitrogen heterocyclic ring micromolecule modified polyethyleneimine polymer derivative provided by the invention has immunostimulatory activity. Besides, the polymer derivative material provided by the invention can be simply mixed with a protein antigen to form nanoparticles, so that efficient loading of the protein antigen is realized, the delivery efficiency of the protein antigen to lymph nodes is improved, and the polymer derivative material can be used for preparing a novel nano vaccine preparation.

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.

The present invention relates to antigens, more particularly protein antigens of enterococcal pathogens derived from the protein AdcA that are particularly useful as vaccine components and constructs for therapy and / or prophylaxis of bacterial infections. The present invention further relates to antibodies directed against the antigens of the invention and medical uses thereof.

The invention relates to a novel human immunodeficiency virus envelope protein antigen expressed by mammals. Various embodiments of the invention relate to a polypeptide comprising 1-10 epitopes or more of the HIV envelope protein and a fusion protein, wherein the polypeptide lacks a transmembrane domain of the HIV gp41 protein. Such polypeptides can be expressed in mammalian cells, such as human cells, to produce polypeptides useful, for example, in the development of novel anti-HIV antibodies. The polypeptides described herein and the novel antibodies developed therefrom are generally useful in medical diagnostics, and they can also be used in the prophylactic and therapeutic treatment of HIV.

The invention discloses a porcine reproductive and respiratory syndrome virus (PRRSV) NADC30-like virus GP5 protein antigen epitope peptide, the antigen epitope peptide is a peptide fragment of porcine reproductive and respiratory syndrome virus GP5 protein 155-156 or / and 196-200, and the amino acid sequence of the antigen epitope peptide is 155WR156 or / and 196QWGRP200. The antigen epitope peptide and the monoclonal antibody provided by the invention are used for detecting the NADC30-like PRRSV and detecting the neutralizing antibody of the virus, replace the traditional method for detecting the neutralizing antibody through cell culture, and provide a new tool for researching the PRRSV and preventing and controlling the PRRSV.

Disclosed herein are compositions comprising protein antigens and RNA encoding the same (eg., compositions comprising protein antigens and RNA encoding antigens) that can be used to induce an immune response against SARS-CoV-2. Also disclosed herein are immunogenic compositions and medical preparations comprising the same, and methods of making and using the same. In some embodiments, the technologies provided herein can be used to address and / or overcome immune imprinting in SARS-CoV-2.

The invention relates to preparation, epitope identification and application of a PRV TK protein monoclonal antibody. The amino acid sequence of a light chain variable region of the monoclonal antibody is as shown in SEQ ID NO.2, and the amino acid sequence of a heavy chain variable region of the monoclonal antibody is as shown in SEQ ID NO.3. Meanwhile, the invention provides the PRV TK protein antigen epitope peptide, and the specific amino acid sequence of the PRV TK protein antigen epitope peptide is as shown in SEQ ID NO. 4. According to the research, on the basis that the PRV strain TK protein is successfully expressed, the PRV strain TK protein is purified to serve as an antigen to immunize a mouse, the specific monoclonal antibody aiming at the PRV strain TK protein is prepared by utilizing a hybridoma technology, and an important tool is provided for PRV epidemic strain TK protein structure and function research and subsequent establishment of a PRV specific diagnosis method and related research.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related techniques (e.g., components thereof and / or methods related thereto) for delivery of malaria protein antigens. The present disclosure provides, among other things, polyribonucleotides encoding malaria protein antigens.

The present application provides a recombinant protein antigen of Acinetobacter baumannii BA71_01558, a preparation method and its application, and relates to the field of biomedical technology. The amino acid sequence of the recombinant protein antigen of Acinetobacter baumannii BA71_01558 of the present invention is shown in SEQ ID NO.1. The preparation process of the recombinant protein antigen of Acinetobacter baumannii BA71_01558 provided by the present application is simple, the operation steps are easy to control and easy to implement, and the obtained recombinant protein of Acinetobacter baumannii BA711_01558 has a high purity and a high yield, and is suitable for large-scale production. The vaccine prepared using the recombinant protein antigen of Acinetobacter baumannii BA711_01558 of the present application has no toxic side effects, can produce high-titer antibodies, has a good immune protection effect against Acinetobacter baumannii infection, and is suitable for preparing specific antibodies.

The application discloses a method for improving the sensitivity of a porcine circovirus type 2 Cap protein antigen agar diffusion detection, and belongs to the technical field of veterinary products. The method is as follows: (1) inoculating piglets with a porcine circovirus 2a, 2b and 2d trivalent virus-like particle vaccine, and then separating serum to obtain a porcine circovirus 2a, 2b and 2d trivalent high-immune serum; (2) preparing a high-salt agar plate; (3) diluting the trivalent high-immune serum and the porcine circovirus type 2 Cap protein antigen with a high-salt diluent, respectively, and then adding the diluted trivalent high-immune serum and the porcine circovirus type 2 Cap protein antigen into holes of the agar plate, and incubating at 35-37 DEG C for 20-24 h to complete the detection. The application uses high-immune serum and an improved agar diffusion method to quantitatively detect the content of PCV2 Cap protein, and avoids the defects of low tolerance to buffer reagents and poor detection specificity of the commonly used BCA or Bradford protein content detection method.

The invention provides a nano-selenium mucosal vaccine preparation, a preparation method, application and a vaccine. The nano-selenium mucosal vaccine preparation is specifically a nano-selenium mucosal vaccine preparation which is prepared by using chicken ovalbumin (OVA) as a protein antigen and modifying nano-selenium with polyethylene glycol (PEG). The invention aims to provide a nano-selenium mucosal vaccine preparation capable of overcoming mucosal barrier, successfully presenting antigen and inducing powerful immune response and a vaccine containing the preparation.

The filed of the present invention relates to immunotherapeutic peptides, peptide binding agents, and their use, for example, in the immunotherapy of cancer.